Recent

% | $
Quotes you view appear here for quick access.

Vanda Pharmaceuticals, Inc. Message Board

  • fossilmark fossilmark Jun 4, 2014 9:03 PM Flag

    220 prescriptions in first six weeks seems very strong . . . .

    In the last three years, revenue has been $31M, $33M, and $34M. Analyst consensus is $45M, implying about $10M expected from Hetlioz. At $84,000 per patient per year, that's 120 patient years of therapy or 240 patient half years of therapy. Of course there will be discounts, prescriptions that don't get filled due to lack of reimbursement, patients who drop off after one or two prescriptions etc. That said, 120 patient years of therapy is 1,440 filled prescriptions. 220 prescriptions in 6 weeks, 110 of which have been reimbursed and filled, when you need 1,440 filled prescriptions to meet analyst consensus seems, like a very strong start!

    Maybe that is why the stock is up 25% today.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
VNDA
12.70+0.46(+3.76%)Aug 3 3:59 PMEDT